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Abstract
Background: Oral squamous cell carcinoma (OSCC) is a frequent neoplasm, which is usually
aggressive and has unpredictable biological behavior and unfavorable prognosis. The
comprehension of the molecular basis of this variability should lead to the development of targeted
therapies as well as to improvements in specificity and sensitivity of diagnosis.
Results: Samples of primary OSCCs and their corresponding surgical margins were obtained from
male patients during surgery and their gene expression profiles were screened using whole-genome
microarray technology. Hierarchical clustering and Principal Components Analysis were used for
data visualization and One-way Analysis of Variance was used to identify differentially expressed
genes. Samples clustered mostly according to disease subsite, suggesting molecular heterogeneity
within tumor stages. In order to corroborate our results, two publicly available datasets of
microarray experiments were assessed. We found significant molecular differences between
OSCC anatomic subsites concerning groups of genes presently or potentially important for drug
development, including mRNA processing, cytoskeleton organization and biogenesis, metabolic
process, cell cycle and apoptosis.
Conclusion: Our results corroborate literature data on molecular heterogeneity of OSCCs.
Differences between disease subsites and among samples belonging to the same TNM class
highlight the importance of gene expression-based classification and challenge the development of
targeted therapies.
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Background
Head and neck squamous cell carcinomas (HNSCC) rank
among the top ten most common cancers worldwide,
with increasing rates in certain areas of the world [1]. They
can occur at different subsites, often invading more than
one, each one with their own particular problems regard-
ing management. In this study, we focused on oral squa-
mous cell carcinoma (OSCC), a frequent neoplasm,
which is usually aggressive and has unpredictable biolog-
ical behavior and unfavorable prognosis. The accumula-
tion of genetic alterations during oral tumorigenesis,
leading to qualitative and quantitative changes in gene
expression, is currently known but still largely unexplored
[2,3]. Unlike estrogen receptor or HER2 in breast cancer,
no biomarkers are currently available for HNSCC progno-
sis, which depends largely on the stage at presentation,
with the most important prognostic factor being the pres-
ence of neck node metastases [4]. Improvements in specif-
icity and sensitivity of diagnosis and in disease
monitoring depend on the elucidation of the biological
and molecular mechanisms underlying tumor develop-
ment. In this context, large-scale transcriptome analysis
may be used to assess patterns of gene expression, provid-
ing an opportunity to investigate the complex cascade of
molecular events leading to tumor development and pro-
gression [5,6].
Two recent publications have examined the global gene
expression profiles of OSCC, both addressing the impor-
tance of understanding the molecular complexity of this
malignancy [7,8]. Unlike those authors, we did not focus
on molecular differences between OSCC and normal
mucosa, but we compared gene expression profiles of
OSCC samples from different anatomic subsites. The bio-
logic behavior of OSCC cannot be predicted and clinical
reports suggest that molecular heterogeneity of anatomic
subsites could play an important role in this scenario. For
instance, cancer of the tongue seems to grow faster than
other oral cavity cancers, with cervical metastases occur-
ring more frequently in such cancers[9]. Moreover, signif-
icant differences between floor of the mouth and tongue
cancers in response to combined surgery and radiotherapy
have been reported [10].
In order to evaluate molecular differences between OSCC
anatomic subsites, we investigated samples of primary
tongue and floor of the mouth tumors, and their corre-
sponding surgical margins, in respect to their gene expres-
sion profile by means of DNA microarrays.
Methods
We selected samples of primary tongue and floor of the
mouth tumors, and their corresponding surgical margins,
from 9 male patients during surgery for squamous cell car-
cinomas. Samples consisted of either small tumors but
already with evidences of metastasis (T2N+), or larger,
non-metastatic samples (T3N0). Patients had a history of
tobacco and alcohol abuse and no prior cancer treatment.
A full description of the clinical data, including tumor
stage is provided in Additional File 1. All participants pro-
vided written consent and the research protocol was
approved by review boards of all involved institutions.
Analysis of haematoxylin and eosin-stained sections indi-
cated that each OSCC sample contained at least 70%
tumor cells and the corresponding surgical margins were
reported "tumor-free". Total RNA was extracted with TRI-
ZOL Reagent (Invitrogen). Tissues adjacent to resected
tumors were grouped into two pools of RNA for microar-
ray analysis, corresponding to T2N+ and T3N0 samples,
due to the limited amounts of tumor-free margin availa-
ble in most cases.
Microarray experiments were carried out using CodeLink
Whole Genome Bioarrays (GE Healthcare) and arrays
were scanned on a GenePix 4000B Array Scanner (Axon
Instruments), according to the recommended scanning
procedures and settings. The data were treated with Code-
Link feature extraction software v.4.0. A normalized signal
for each transcript was obtained through quantile normal-
ization [11]. The array design and raw data files are avail-
able at the Gene Expression Omnibus database (GEO)
under the accession number GSE9792. For global gene
expression visualization, we used hierarchical clustering
and Principal Components Analysis (PCA). Hierarchical
clustering was performed using the Euclidean distance
and the average linkage algorithm. One-way ANOVA was
used to identify significant differences in the dataset. All
the above-mentioned analyses were generated using
Partek® software version 6.3 Copyright© 2007 Partek Inc.,
St. Louis, MO, USA. Functional annotations of differen-
tially expressed genes were performed using Database for
Annotation, Visualization and Integrated Discovery [12]
using the parameters Gene Ontology (GO) Molecular
Process term level 5 and KEGG Pathways (Kyoto Encyclo-
pedia of Genes and Genomes)[13].
In order to corroborate our findings, two publicly availa-
ble microarray datasets on OSCC were used in addition to
our data (GEO accession number GSE3524 and ArrayEx-
press accession number TABM302). Both experiments
were carried out using Affymetrix HG-U133 GeneChips;
GSE3524 corresponds to the profiling of 7 tongue and 9
floor of the mouth samples, while TABM302 corresponds
to the profiling of 18 tongue samples and 10 samples
reported as oral cavity. Statistical analysis and functional
annotation of the differentially expressed genes followed
the procedures previously described for our dataset (Addi-
tional Files 2 and 3).BMC Research Notes 2008, 1:113 http://www.biomedcentral.com/1756-0500/1/113
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Results and Discussion
By analyzing the dendogram resulting from hierarchical
clustering and the PCA, we observed that OSCC samples
did not group according to their pathological stages (Fig-
ures 1 and 2, respectively). In agreement with previous
reports [14,15], two major clusters reflected differences in
global gene expression between non-tumoral tissues
(cluster 1) and tumor samples (cluster 2). Tumor samples
clustered mostly, but not exclusively, according to disease
anatomic subsites. This result suggests molecular hetero-
geneity within TNM classes and corroborates previous
data published by Ziober et al. [15] and Chung et al[16].
In the later study, there were no consistent differences in
gene expression among HNSCC subsites, but samples
from oral cavity seemed more heterogeneous than sam-
ples from other sites when expression patterns were eval-
uated. Few studies have aimed to understand the
molecular background of OSCC. In the context of molec-
ular target therapies, drugs are designed to interact with
specific molecules present in certain types or subtypes of
tumors. Due to the heterogeneity within HNSCC, a thor-
oughly comprehension of the molecular characteristics
underlying its subsites is needed before efficient therapy
can be achieved.
Differential gene expression profiles
Using hierarchical clustering and PCA, two main groups
of tumor samples (2a and 2b) were observed (Figure 1).
Each group contained, mostly, either tongue or floor of
the mouth samples. Differentially expressed genes
between the two clusters were identified using ANOVA
(Additional File 4). These genes (total number 1579) were
functionally annotated using Gene Ontology (GO) and
KEGG terms in an attempt to understand major molecular
differences between the groups (Tables 1 and 2). Due to
our small sample number, our results were compared
with two additional OSCC microarray datasets, GSE3524
and TABM302. Despite broad differences in experimental
Hierarchical clustering Figure 1
Hierarchical clustering. The analysis was performed using the Euclidean distance and the average linkage algorithm. N1: Sur-
gical margins from T2N+ samples; N2: Surgical margins from T3N0 samples. Case1–9: Tumor samples described in Additional 
File 1.BMC Research Notes 2008, 1:113 http://www.biomedcentral.com/1756-0500/1/113
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design, probe sets, and possibly genetic background, some
findings were consistent and are pointed out below.
Extensive differences in gene expression between clusters
2a and 2b were observed in respect to translation and
mitosis-related GO terms (GO:0006412:translation,
GO:0000087:M phase of mitotic cell cycle;
GO:0007067:mitosis; GO:0000279:M phase). Transla-
tion initiation is regulated in response to mitogenic stim-
ulation, thus coupled with cell cycle progression and cell
growth. Several alterations in translational control occur
in cancer, but there is still much to be discovered about
their role in cancer development and progression [17].
Changes in the expression or availability of components
of the translational machinery can lead to global changes,
such as an increase in the overall rate of protein synthesis
and translational activation of the mRNA molecules
involved in cell growth and proliferation. In agreement,
differences between the two clusters were enriched in GO
terms Ribonucleotide Biosynthetic Process, RNA Process-
Three-dimensional Principal Components Analysis Figure 2
Three-dimensional Principal Components Analysis. FOM: Floor of the mouth, NO: Surgical margins (N1: Surgical mar-
gins from T2N+ samples; N2: Surgical margins from T3N0), TO: Tongue.BMC Research Notes 2008, 1:113 http://www.biomedcentral.com/1756-0500/1/113
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Table 1: GO terms containing differentially expressed genes between OSCC subsite-related clusters
GO Term p Value Gene Symbol
GO:0006412:translation 1.55E-07 C15ORF15, CEBPG, DARS2, DDX1, DENR, EEF1A1, EIF1, EIF1AY, 
EIF2B1, EIF2B3, EIF2C4, EIF3S7, EIF4A1, EIF4EBP1, ETF1, GSPT1, 
HARSL, HBS1L, IGF2BP2, JTV1, LARS, LOC151507, MRPL1, MRPL10, 
MRPL20, MRPL22, MRPL35, MRPL37, MRPL45, MRPL9, MRPS15, 
MRPS16, MRPS7, MTIF2, NARS2, NFKB1, PAIP2, PDF, PET112L, PRG3, 
RPL13, RPL18A, RPL19, RPL26, RPL26L1, RPL27, RPL35A, RPL36A, 
RPL4, RPL6, RPL7, RPL7A, RPLP1, RPS14, RPS15A, RPS2, RPS24, RPS26, 
RPS26E, RPS26L, RPS27, RPS27A, RPS3, RPS3A, RPS7, SAMD4A, SARS, 
SECISBP2, SLA/LP, SRP9, STAT5B, TNIP1, TRIP11, TSFM, TUFM, 
WBSCR1, ZFP36L1
GO:0000087:M phase of mitotic cell cycle 5.53E-06 ANAPC11, APRIN, AURKB, BIRC5, C20ORF172, CCNB1, CCNK, 
CDC2L5, CLASP2, CSPG6, EML4, FAM33A, GTSE1, KIF2C, KNTC1, 
LUZP5, MAD2L1, MPHOSPH6, NUDC, PAM, PB1, PRMT5, RAD21, 
RAN, RUVBL1, SMC4L1, SPAG5, SPBC25, STAG1, SUGT1, TARDBP, 
TTN, TXNL4B, ZWINT
GO:0007067:mitosis 1.21E-05 ANAPC11, APRIN, AURKB, BIRC5, C20ORF172, CCNB1, CCNK, 
CDC2L5, CLASP2, CSPG6, EML4, FAM33A, GTSE1, KIF2C, KNTC1, 
LUZP5, MAD2L1, NUDC, PAM, PB1, PRMT5, RAD21, RAN, RUVBL1, 
SMC4L1, SPAG5, SPBC25, STAG1, SUGT1, TARDBP, TTN, TXNL4B, 
ZWINT
GO:0006325:establishment and/or maintenance of 
chromatin architecture
1.37E-05 ARID1B, BAZ1B, C11ORF30, CBX3, CDYL, CEBPG, CHAF1A, CHD2, 
CHD9, EHMT2, EPC1, FBXL11, GCN5L2, H2AFX, H2AFZ, HDAC4, 
HDAC6, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, 
HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST3H3, 
HMGB2, HP1BP3, JARID1B, JMJD1C, JMJD2C, MBD3, MCM2, MLL3, 
NAP1L1, NCOR1, NSD1, PB1, PRMT5, RBBP4, RBL1, RERE, RUVBL1, 
SAS10, SET, SMARCB1, SMARCC1, WHSC1
GO:0000279:M phase 2.05E-05 ANAPC11, APRIN, AURKB, BIRC5, C20ORF172, C8ORF1, CCNB1, 
CCNK, CDC2L5, CLASP2, CSPG6, CTA-250D10.11, EML4, FAM33A, 
GTSE1, H2AFX, KIF2C, KNTC1, LUZP5, MAD2L1, MPHOSPH6, 
NUDC, PAM, PB1, PRMT5, RAD21, RAN, REC8L1, RUVBL1, SMC4L1, 
SPAG5, SPBC25, STAG1, SUGT1, TARDBP, TTN, TXNL4B, ZWINT
GO:0006323:DNA packaging 2.14E-05 ARID1B, BAZ1B, C11ORF30, CBX3, CDYL, CEBPG, CHAF1A, CHD2, 
CHD9, EHMT2, EPC1, FBXL11, GCN5L2, H2AFX, H2AFZ, HDAC4, 
HDAC6, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, 
HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST3H3, 
HMGB2, HP1BP3, JARID1B, JMJD1C, JMJD2C, MBD3, MCM2, MLL3, 
NAP1L1, NCOR1, NSD1, PB1, PRMT5, RBBP4, RBL1, RERE, RUVBL1, 
SAS10, SET, SMARCB1, SMARCC1, WHSC1
GO:0009260:ribonucleotide biosynthetic process 2.12E-04 ADK, ADSL, ATP5B, ATP5C1, ATP5F1, ATP5G3, ATP5H, ATP5L, 
ATP5O, ATP6V1C1, CTPS, IMPDH1, NME2, PAICS, PAPSS1, PAX8, 
UMPS
GO:0006281:DNA repair 2.87E-04 APEX1, ATRX, BLM, C11ORF30, C2ORF13, C8ORF36, CEBPG, 
CHAF1A, CIB1, CSNK1D, CSPG6, ERCC8, FANCC, FEN1, FLJ40869, 
H2AFX, HMGB2, LIG1, MBD4, MDC1, MGMT, MLH1, MSH3, NUDT1, 
POLE2, RAD18, RAD21, RBX1, REV1L, RPA3, SMC5L1, SOD2, XRCC5
GO:0006396:RNA processing 8.86E-04 AQR, BCAS2, C14ORF172, C1ORF19, CROP, CSTF2T, DDX1, 
DDX46, DDX5, DHX35, DICER1, ERN2, EXOSC1, EXOSC3, GEMIN5, 
HNRPA2B1, HNRPD, HSA9761, LOC113179, LSM3, MAGOH, 
NHP2L1, NOL5A, PABPN1, PDCD11, POP4, PPIL3, PRPF3, PRPF38B, 
RPS14, SARS, SAS10, SF3B14, SF3B5, SLBP, SMN1, SMN2, SNRPA1, 
SNRPF, SR140, SRRM2, TARDBP, TXNL4B, U2AF1, UTP11L, UTP15, 
ZCRB1, ZNF265
GO:0016071:mRNA metabolic process 9.55E-04 AQR, C1ORF19, CSTF2T, DCP1A, DDX1, DDX46, DDX5, DHX35, 
ERN2, GEMIN5, GSPT1, HNRPA2B1, HNRPD, LSM3, LSMD1, MAGOH, 
NHP2L1, PABPN1, PPIL3, PRPF3, PRPF38B, SF3B14, SF3B5, SLBP, SMG7, 
SMN1, SMN2, SNRPA1, SNRPF, SRRM2, TARDBP, TXNL4B, U2AF1, 
ZCRB1, ZFP36L1, ZNF265BMC Research Notes 2008, 1:113 http://www.biomedcentral.com/1756-0500/1/113
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ing and mRNA Metabolic Process as well as in KEGG Pro-
teasome, Cell Cycle, TGFB Signaling and Ribosome
Pathways. Components of the translation machinery and
related pathways represent good targets for cancer therapy
[18,19]. The differential expression of a number of genes
involved in such processes suggests that the efficacy of oral
cancer therapy should vary depending on the tumor sub-
site. Molecular mechanisms leading to differences in gene
expression (i.e variations in mRNA sequences, changes in
the availability of the translational machinery compo-
nents, and activation of translation through abnormally
activated signal transduction pathways) deserve to be
investigated.
Differences in the expression of cell cycle progression-
related genes were also observed in both GEO (GSE3524)
and ArrayExpress (TABM302) datasets. In respect to the
former, several genes associated with the KEGG MAPK
Signaling Pathway presented differential expression when
tongue samples were compared with floor of the mouth
samples. Similar results were observed for GO terms con-
cerning transcriptional regulation and apoptosis (Addi-
tional File 5). In agreement with our results, TABM302
dataset showed differential expression in genes associated
with the GO terms Maintenance of Chromatin Architec-
ture and DNA Packaging, both essential in cell cycle-
related processes, and with the KEGG Ribosome Pathway
(Additional File 6). Proliferation and cell death are also
regulated by genes associated with the GO terms Small
GTPase Mediated Signal Transduction and Regulation of
Ras Protein Signal Transduction, both represented several
times in the list of differentially expressed genes of the
TABM302 dataset.
With respect to cell cycle and apoptosis, we also observed
the over-expression in cluster 2b of three genes involved
in the regulation of p27 phosphorylation during cell cycle
progression (CKS1B, RBX1 and SKP1A) and genes from
the MCM complex (minichromosomal maintenance
genes), including MCM7 (Additional File 4). MCM7 pro-
tein is a marker for proliferation and it is upregulated in
different tumors including neuroblastoma, prostate, cervi-
cal and hypopharyngeal carcinomas [20]. SKP1A, MCM3,
MCM6 and MCM7 were also differentially expressed in
TABM302 dataset (Additional File 3), however, their over-
expression was observed in tongue samples.
Widespread differences were also observed in oxidative
phosphorylation pathways (Tables 2 and 3). Genes
belonging to KEGG Oxidative Phosphorylation and Cit-
rate Cycle (TCA cycle) Pathways were over-expressed in
cluster 2b. Oxidative phosphorylation of ADP to ATP
accompanies the oxidation of a metabolite through the
operation of the respiratory chain. According to Warburg
[21], alterations of respiratory machinery should result in
compensatory increase in glycolytic ATP production and
lead to carcinogenesis. In fact, malignant cells meet their
energy (ATP) needs by glycolysis rather than through oxy-
dative phosphorylation, probably an adaptation to
hypoxia that develops as tumor grows [22]. In accordance
with our results, some authors have recently found a
bioenergetic signature in several human tumors [23]. Our
observations suggest that distinct OSCC subsites differ on
their glycolytic phenotype, a matter that deserves further
investigation and may impact tumor progression manage-
ment as well as therapy outcome.
Table 2: Major KEGG pathways containing genes differentially expressed between OSCC subsite-related clusters
KEGG Term p Value Gene Symbol
hsa03050:Proteasome 4.04E-03 PSMA1, PSMA2, PSMA4, PSMA5, PSMB2, PSMB6, PSMD12
hsa04350:TGF-beta signaling pathway 6.29E-02 ACVR2A, BMP7, CHRD, E2F4, PPP2R2B, RBL1, RBX1, SKP1A, SMAD4, SMURF2, 
TGFBR2, THBS3
hsa03010:Ribosome 2.80E-04 C15ORF15, MRPS7, RPL13, RPL18A, RPL19, RPL26, RPL27, RPL35A, RPL36A, RPL6, 
RPL7, RPS15A, RPS2, RPS24, RPS26, RPS26E, RPS26L, RPS27, RPS3, RPS3A, RPS7
hsa05210:Colorectal cancer 8.24E-03 AXIN2, BAX, BIRC5, CASP9, FZD8, HRAS, IGF1R, KRAS, MAPK9, MLH1, MSH3, NRAS, 
RALGDS, SMAD4, SOS1, TGFBR2
hsa00020:Citrate cycle (TCA cycle) 1.96E-02 ACLY, IDH3A, IDH3B, MDH2, SDHA, SDHB, SDHD
hsa01030:Glycan structures – biosynthesis 1 2.79E-02 ALG14, ALG9, B4GALT5, CHST11, CSS3, EXT1, FUT8, GALNACT-2, GALNT1, 
GALNTL4, HS3ST2, HS3ST3B1, MGAT5, OGT, ST3GAL1, XYLT1
hsa04110:Cell cycle 8.28E-03 ANAPC11, CCNB1, CDK4, DBF4, MAD2L1, MCM2, MCM3, MCM4, MCM5, MCM7, 
PTTG2, RBL1, RBX1, SKP1A, SMAD4, YWHAE, YWHAQ
hsa00190:Oxidative phosphorylation 2.50E-10 ATP5B, ATP5C1, ATP5F1, ATP5G3, ATP5H, ATP5L, ATP5O, ATP6V1C1, COX17, 
COX5A, COX6A1, COX6B1, COX7A2, COX7B, COX7C, CYC1, NDUFA12, 
NDUFA7, NDUFAB1, NDUFB10, NDUFB8, NDUFB9, NDUFS1, NDUFS4, NDUFS5, 
NDUFV2, PPA2, RP3-405J24.3, SDHA, SDHB, SDHD, UQCRB, UQCRFS1, UQCRH
hsa04540:Gap junction 8.56E-02 ADCY2, ADCY5, ADCY6, CSNK1D, GNAQ, GUCY1A3, HRAS, K-ALPHA-1, KRAS, 
NRAS, PDGFD, PRKG1, SOS1, TUBA6, TUBB6BMC Research Notes 2008, 1:113 http://www.biomedcentral.com/1756-0500/1/113
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Genes related to KEGG Oxidative Phosphorylation Path-
way also showed differences in expression in GSE3524
dataset when subsites were compared; the same was
observed for genes related to the GO term Organelle ATP
Synthesis Coupled Electron Transport (Additional File 5).
The expression of several cytochrome oxidases and
ATPases was also distinct between subsites in TABM302
(Additional File 3).
KEGG Pathway analysis revealed genes over-expressed in
cluster 2a which are associated with gap junctions and
adherens junctions, as well as cytoskeleton organization
and biogenesis (Table 4), including ACTN, DOCK1, GSN,
ITG, LIMK, RAS, SOS, SSH and TIAM1. In agreement with
our data, genes related to KEGG Regulation of Actin
Cytoskeleton and Adherens Junction Pathways were also
found differentially expressed in TABM302 (Additional
File 6). Cancer therapy has focused on such pathways. For
example, microtubule-targeted drugs interfere with the
ability of the cancer cells to divide and multiply by dis-
rupting microtubules [24]. Gene-silencing may reduce
expression of proteins involved in regulating the actin
cytoskeleton, as LIMK, rendering cells more responsive to
anticancer agents [25]. Therefore, molecular differences
between OSCC subsites may affect sensitivity to chemo-
therapy.
In addition to the data presented above, several genes
over-expressed in cluster 2b have been previously associ-
ated with oral cancer, such as GSTM1, IL8, MGMT, NFKB1
and NUDT1; as well as with pancreatic cancer (APEX1,
CDK4, FANCC, GSTM1, MGMT and SOD2), lung cancer
(APEX1, CASP9, GSTM1, HSPA8, IL8, LIG1, MBD4,
MGMT, MLH1, NUDT1 and SOD2), colorectal cancer
(APEX1, BLM, GSTM1, IL8, MGMT, MLH1, NFKB1,
NUDT1, RFC1, SOD2 and UMPS) and bladder cancer
(APEX1, GSTM1, IL8, LIG1, MGMT and SOD2) (Addi-
tional File 4). We believe the differential expression
between anatomic subsites of genes known to be involved
in tumorigenesis deserves further investigation.
Conclusion
Gene expression profiling of lymph node positive and
lymph node negative HNSCC has been addressed in the
literature [14,15,26,27]. Besides the differences in study
designs, the lack of consistency concerning HNSCC gene
expression signatures could be due to gene expression var-
iation related to subsites. This is a preliminary study and
as such presents results on a small number of samples.
Table 3: KEGG enriched terms containing genes over-expressed in cluster 2b
KEGG Term p Value Gene Symbol
hsa00190:Oxidative phosphorylation 6.84E-16 ATP5B, ATP5C1, ATP5F1, ATP5G3, ATP5H, ATP5L, ATP5O, COX17, COX5A, COX6A1, 
COX6B1, COX7A2, COX7B, COX7C, CYC1, NDUFA12, NDUFA7, NDUFAB1, 
NDUFB10, NDUFB8, NDUFB9, NDUFS1, NDUFS4, NDUFS5, NDUFV2, PPA2, RP3-
405J24.3, SDHA, SDHB, SDHD, UQCRB, UQCRFS1, UQCRH
hsa03050:Proteasome 2.58E-04 PSMA1, PSMA2, PSMA4, PSMA5, PSMB2, PSMB6, PSMD12
hsa04110:Cell cycle 0.001169541 ANAPC11, CCNB1, CDK4, DBF4, MAD2L1, MCM2, MCM3, MCM5, MCM7, PTTG2, RBX1, 
SKP1A, YWHAE, YWHAQ
hsa00020:Citrate cycle (TCA cycle) 0.001533882 ACLY, IDH3A, IDH3B, MDH2, SDHA, SDHB, SDHD
hsa03010:Ribosome 9.30E-07 C15ORF15, MRPS7, RPL13, RPL18A, RPL19, RPL26, RPL27, RPL35A, RPL6, RPL7, RPS15A, 
RPS2, RPS24, RPS26, RPS26E, RPS26L, RPS27, RPS3, RPS3A, RPS7
Table 4: KEGG enriched terms containing genes over-expressed in cluster 2a
KEGG Term p Value Gene Symbol
hsa04510:Focal adhesion 0.075632796 ACTN3, DOCK1, FLNB, HRAS, IGF1R, ITGA11, KRAS, NRAS, PARVG, PDGFD, 
PTK2, SOS1, THBS3
hsa04810:Regulation of actin cytoskeleton 0.026522502 ACTN3, CYFIP2, DOCK1, GSN, HRAS, ITGA11, KRAS, LIMK2, NRAS, PTK2, RDX, 
RRAS2, SOS1, SSH2, TIAM1
hsa04540:Gap junction 0.007365075 ADCY2, ADCY5, ADCY6, GNAQ, GUCY1A3, HRAS, KRAS, NRAS, PDGFD, 
PRKG1, SOS1
hsa04520:Adherens junction 0.071052621 ACTN3, IGF1R, NLK, PTPRF, SMAD4, TGFBR2
hsa04350:TGF-beta signaling pathway 0.017990954 ACVR2A, CHRD, PPP2R2B, RBL1, SMAD4, SMURF2, TGFBR2, THBS3
hsa05210:Colorectal cancer 0.013445912 AXIN2, BAX, HRAS, IGF1R, KRAS, MSH3, NRAS, SMAD4, SOS1, TGFBR2
hsa01030:Glycan structures – biosynthesis 1 5.16E-05 B4GALT5, CHST11, CSS3, EXT1, FUT8, GALNACT-2, GALNT1, GALNTL4, 
HS3ST2, HS3ST3B1, MGAT5, OGT, ST3GAL1, XYLT1
hsa00532:Chondroitin sulfate biosynthesis 0.027092201 CHST11, CSS3, GALNACT-2, XYLT1
hsa00512:O-Glycan biosynthesis 0.014720589 B4GALT5, GALNT1, GALNTL4, OGT, ST3GAL1BMC Research Notes 2008, 1:113 http://www.biomedcentral.com/1756-0500/1/113
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However, the idea of molecular heterogeneity within
HNSCC is not new. We corroborate previously reported
literature data and we suggest that differences between
anatomic OSCC subsites could impact drug response and
should be considered during the development of targeted
therapies.
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